SABSW
SAB Biotherapeutics, Inc.
Nasdaq Biological Products, (No Diagnostic Substances)
Emerging growth company

Key Financials

Net Income
$13.3M
↑ 138.9%
Revenue
$0
↓ 100.0%
EPS (Diluted)
$-0.79
↑ 78.5%
Operating Income
$-48953363
↓ 14.1%
Total Assets
$172.8M
↑ 291.0%
Shareholders' Equity
$151.5M
↑ 483.4%
Total Liabilities
$21.3M
↑ 17.0%
Cash & Equivalents
$10.5M
↑ 18.0%

Recent SEC Filings

Form Type Filed Date Link
8-K 10/13/2026 View on SEC
4 9/18/2026 View on SEC
424B3 8/21/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G 8/12/2026 View on SEC

Company Information

Field Value
Ticker SABSW
Company Name SAB Biotherapeutics, Inc.
CIK 1833214
Sector Biological Products, (No Diagnostic Substances)
Industry
Emerging growth company
Exchange Nasdaq
SIC Code 2836
SIC Description Biological Products, (No Diagnostic Substances)
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 305-845-2813